Skechers withdraws annual guidance amid trade uncertainty, citing tariff impacts and production challenges, but analysts remain optimistic about the company's long-term prospects.
Roche reports strong Q1 sales, driven by newer medicines, and confirms FY25 outlook despite challenges in Diagnostics Division.
Skechers withdraws annual guidance amid trade uncertainty, citing tariff impacts and production challenges, but analysts remain optimistic about the company's long-term prospects.
Roche reports strong Q1 sales, driven by newer medicines, and confirms FY25 outlook despite challenges in Diagnostics Division.